Preparation method and application of polysulfonic acid mucopolysaccharide

The preparation of polysulfonic acid mucopolysaccharide MPS through the degradation and sulfonication of chondroitin sulfate has solved the problem of insufficient research on industrial production of polysulfonic acid mucopolysaccharides and whitening, anti-aging and anti-inflammatory, and achieved its potential application in cosmetics.

CN118994438APending Publication Date: 2024-11-22贵州中森医药有限公司
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411261772.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The industrial production of polysulfonic acid mucopolysaccharides is difficult and there is little research on whitening, anti-aging and anti-inflammatory, which limits its development in cosmetics applications.

Method used

Polysulfonic acid mucopolysaccharide MPS is prepared by degradation and sulfonation of chondroitin sulfate. Hydrogen peroxide dissolving and chlorosulfonate formamide sulfonation technology are used to control the molecular weight within the range of 5-15 kDa, combined with high-performance liquid phase and nuclear magnetic resonance analysis. Technology confirms its chemical structure.

Benefits of technology

The industrial production of polysulfonic acid mucopolysaccharide MPS has been realized, and its biological activities to inhibit tyrosinase activity, anti-cellular aging and inflammation have potential whitening, anti-aging and anti-inflammatory effects, and is suitable for the development of cosmetics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention provides a multi-sulfonic acid mucopolysaccharide MPS, preparation and structural characteristics thereof, and application of the MPS in whitening, anti-aging and anti-inflammatory drugs. According to the present invention, the structural characteristics of the MPS are mainly obtained from chondroitin sulfate A (CSA) through H2O2 degradation and sulfonation modification of the degradation product, and the in vitro experiment results prove that the S-LMCS can inhibit the activity of tyrosinase in B16 cells, inhibit the cell senescence of a H2O2-induced HaCaT senescence model, and inhibit the release of nitric oxide (NO) in RAW264.7 cells; therefore, the multi-sulfonic acid mucopolysaccharide MPS has whitening, anti-aging and anti-inflammatory effects, and the polysaccharide is expected to become a potential effective additive of novel cosmetics and is used for developing the cosmetics.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a use of mucopolysaccharide polysulfate, and more specifically to a method for preparing mucopolysaccharide polysulfate MPS by degradation and sulfonation using chondroitin sulfate A as a raw material, and also provides a preparation method thereof, and the use thereof in anti-inflammatory, whitening and anti-aging processes. Background Art

[0002] Mucopolysaccharides are a class of nitrogen-containing sulfonated polysaccharides that are widely present in the connective tissues and cells of various organs of mammals. They have the functions of maintaining the moisture of connective tissues, regulating the distribution of metal ions in tissues, and lubricating joints. Important mucopolysaccharides include heparin, dermatan sulfate, heparan sulfate, chondroitin sulfate, and hyaluronic acid, which are chain polysaccharides formed by repeated connection of different disaccharide units. Polysulfonated mucopolysaccharides have become a hot topic in research and application because of their functions of inhibiting blood coagulation, preventing thrombosis, and anti-inflammatory. Among them, mucopolysaccharide polysulfate (MPS) is composed of disaccharide repeating units of β-D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine with several sulfonic acid groups (-SO3H), and the molecular weight is between 5-15 kDa. For example, polysulfonated mucopolysaccharide cream (trade name: Hiliaot) is clinically used for varicose phlebitis and its postoperative recovery treatment, and the elimination of contusions, edema, scars, and acne marks. Polysulfonated mucopolysaccharide has good biological activity and can be used as a raw material for the development of cosmetics, but the compound has defects such as complex production process, harsh reaction conditions and high environmental pollution. At present, few domestic companies carry out industrial production of it. At the same time, there is little research on the whitening, anti-aging and anti-inflammatory aspects of the polysaccharide, which limits the application of polysulfonated mucopolysaccharide in cosmetics and the development of related products. Summary of the invention

[0003] The present invention uses a simple and effective process and method for preparing polysulfonated mucopolysaccharide MPS that meets pharmaceutical specifications using chondroitin sulfate A (CSA) as a raw material, which can realize industrial production. In vitro experiments have shown that the polysaccharide can inhibit tyrosinase activity in B16 cells, inhibit cell senescence in the HaCaT aging model induced by H2O2, promote cell proliferation in the RAW264.7 cell inflammation model induced by LPS lipopolysaccharide, and inhibit the release of nitric oxide (NO) in RAW264.7 cells. Therefore, the polysulfonated mucopolysaccharide MPS has potential whitening, anti-aging and anti-inflammatory effects, and the polysaccharide is expected to become an effective cosmetic ingredient and be used in the development of new cosmetics.

[0004] To solve the above-mentioned purpose, the present invention provides a polysulfonated mucopolysaccharide MPS, which is composed of disaccharide repeating units of β-D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine with several sulfonic acid groups (-SO3H), and has a molecular weight between 5-15 kDa. Preferably, the MPS has the following structure:

[0005] Where n = 11-13 The molecular weight of the mucopolysaccharide polysulfate MPS is in the range of 5-15 kDa, preferably 8.39 kDa.

[0006] (1) Degradation of chondroitin sulfate A (CSA): CSA was dissolved in 30% hydrogen peroxide solution and degraded in an oil bath at 100 °C for 6 h. NaOH was added to terminate the reaction and promote the decomposition of H2O2. The reaction solution was concentrated and dialyzed against deionized water (MWCO: 3,500 Da) for 48 h. The liquid in the dialysis bag was collected and freeze-dried to obtain degraded polysaccharide. (2) Sulfonation of degraded polysaccharides: First, dissolve the degraded polysaccharides in formamide solution, slowly add a mixed acid solution of chlorosulfonic acid and formamide, and continue heating and stirring in a 50 °C oil bath for 3 h. Turn off the heating, add 4 M NaOH solution to terminate the reaction and adjust the pH value of the solution to neutral. The reaction solution is loaded into a dialysis tape (MWCO: 3,500 Da) and dialyzed with deionized water for 24 h. The dialyzed solution is concentrated and freeze-dried to obtain polysulfonated mucopolysaccharide MPS.

[0007] (3) Identification of special functional groups and chemical structure of MPS: The purity and molecular weight are determined by high performance liquid chromatography, and the special functional groups and chemical structure are identified by infrared and nuclear magnetic resonance.

[0008] (1) Study on the inhibition of B16 cell proliferation by MPS and the biological activity of its tyrosinase: The MTT experiment was used to investigate the effect of MPS on B16 cell proliferation and cell morphology; the effect of MPS on the tyrosinase activity in B16 cells was investigated by detecting the catalysis of levodopa by tyrosinase in B16 cells.

[0009] (2) Study on the biological activity of MPS in inhibiting H2O2-induced senescence of HaCaT cells: HaCaT cells were treated with hydrogen peroxide to construct a cell senescence model. The H2O2 concentration required for the optimal senescence model was explored through the MTT cell proliferation experiment. At the same time, the effect of MPS on the proliferation of aged HaCaT cells was explored.

[0010] (3) Study on the biological activity of MPS in inhibiting LPS-induced inflammation in RAW264.7 cells: An inflammatory model was established by administering 1 μg / mL of LPS to RAW264.7 cells. The proliferation of RAW264.7 cells stimulated by LPS was detected by MTT cell proliferation assay. At the same time, the NO content in the culture supernatant of RAW264.7 cells stimulated by LPS after treatment with different concentrations of MPS was detected by NO detection kit.

[0011] The present invention also provides the use of polysulfonated mucopolysaccharide MPS as a tyrosinase inhibitor drug, an anti-aging inhibitor additive, an inflammation inhibitor and other drugs. Experimental results show that MPS can inhibit tyrosinase activity in B16 cells, inhibit cell senescence in the HaCaT aging model induced by H2O2, and inhibit the release of nitric oxide (NO) in RAW264.7 cells. Therefore, the polysulfonated mucopolysaccharide MPS has potential whitening, anti-aging and anti-inflammatory effects, and the polysaccharide is expected to become a potential new effective cosmetic additive and be used in the development of cosmetics.

[0012] The present invention mainly solves the problem of the difficulty in the current industrial production of polysulfonated mucopolysaccharide, focuses on the process of preparing polysulfonated mucopolysaccharide MPS through chondroitin sulfate A and the chemical structure of the obtained MPS analyzed and characterized by modern analytical technology. The main difficulty of the present invention is to obtain polysulfonated mucopolysaccharide MPS with a specific molecular weight range and multiple sulfonic acid groups through hydrogen peroxide degradation technology and chlorosulfonic acid formamide sulfonation technology. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 The purity chart of the CSA HPLC of the raw material drug in Preparation Example 1; Figure 2 The purity chart of the degraded polysaccharide HPLC of CSA prepared in Preparation Example 1; Figure 3 The purity chart of the MPS prepared in Preparation Example 1 by high performance liquid chromatography; Figure 4 The infrared spectra of CSA and MPS in Preparation Example 1 are shown below; Figure 5 To prepare CSA and MPS in Example 1 1 H-NMR spectrum; Figure 6 To prepare CSA and MPS in Example 1 13 C-NMR spectrum; Figure 7 HSQC spectra of CSA and MPS in Preparation Example 1; Figure 8To prepare the bright field image of the effect of the positive drugs arbutin and MPS on the morphology of B16 cells in Example 1; Fig. 9 This is a graph showing the MTT test results of the effect of MPS on B16 cell proliferation in Preparation Example 1; Fig.10 This is a graph showing the experimental results of the effects of arbutin and MPS on tyrosinase activity in B16 cells in Preparation Example 1; Fig.11 This is a graph showing the MTT test results of the effects of different concentrations of H2O2 on the proliferation of HaCaT cells in Example 1; Fig.12 This is a graph showing the MTT test results of the effect of MPS on the proliferation of HaCaT cells in Example 1; Fig.13 This is a graph showing the MTT test results of the effect of MPS on the proliferation of HaCaT cells under 0.8 mM H2O2 treatment in Example 1; Fig.14 This is a graph showing the results of the MTT experiment of the effect of MPS on the proliferation of RAW264.7 cells under the stimulation of lipopolysaccharide LPS in Example 1; Fig.15 This is a graph showing the experimental results of the determination of NO content in the culture supernatant of RAW264.7 cells under the condition of lipopolysaccharide (LPS) stimulation in Preparation Example 1. DETAILED DESCRIPTION

[0014] The present invention is described below by specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be understood as illustrative rather than limiting the scope of the present invention, and the essence and scope of the present invention are limited only by the claims. For those skilled in the art, various changes or modifications to the material components and dosages in these embodiments, without departing from the essence and scope of the present invention, also belong to the protection scope of the present invention. The raw materials used in the present invention, such as chondroitin sulfate A (CSA), chlorosulfonic acid formamide, etc., are all commercially available.

[0015] 1. Preparation of MPS 1.1 Chondroitin sulfate A was added into 1L of 30% hydrogen peroxide dilution solution (700 mL deionized water + 300 mL hydrogen peroxide (30%)) at a material-liquid ratio of 1:50-3:50 (g / mL), heated to dissolve, and reacted at 70°C for 6 hours. The round-bottom flask was connected with a DC condenser and protected with a balloon. After the reaction was completed, the pH was adjusted to 3-4 with acetic acid, and the reaction solution was concentrated under reduced pressure. After the volume was reduced, it was loaded into a 3,500 Da cutoff dialysis bag and dialyzed with deionized water for 48 hours. The dialyzed liquid was freeze-dried to obtain the degraded polysaccharide.

[0016] 1.2 Take the degraded polysaccharide obtained after freeze-drying and add it to the formamide solution at a material-liquid ratio of 10:1-10:4 (mg / mL), and stir and dissolve it in an oil bath at 50-70°C. Preparation of mixed acid: Slowly add chlorosulfonic acid to the formamide solution (dry and anhydrous) under ice bath conditions, with a volume ratio of 1:3-1:5, and the final solution is a colorless, transparent, oily liquid. Add the formamide solution of degraded polysaccharide to the mixed acid solution, and continue to heat and stir in a 50°C oil bath for 3-4 h. Turn off the heating and adjust the solution pH to between 7-7.5 with 4M NaOH solution, during which a large number of bubbles are generated. The reaction solution is placed in a dialysis bag (3,500 Da cutoff) and dialyzed with deionized water for 24-36 h (the dialysis external solution is replaced every 4 h). After the dialysis internal solution is concentrated to a small volume, it is freeze-dried to obtain MPS, weighed, and stored in a desiccator.

[0017] 2. Molecular weight, purity and structural identification of polysaccharides 2.1 Identification of molecular weight and purity of polysaccharides The molecular weight and purity of the polysaccharide were identified by high performance liquid chromatography. The polysaccharide was dissolved in the mobile phase (0.1 M NaNO3) to prepare a 2 mg / mL solution, and the sample was injected for analysis. The results were as follows: Figure 1 , Figure 2 and Figure 3 As shown, a single symmetrical absorption peak was obtained, and the GPC integration results showed that MPS ( Figure 3 ) has a molecular weight range of 5,000-15,000 Da, preferably 7,766 Da.

[0018] 2.2 Analysis of infrared spectrum and nuclear magnetic resonance spectrum of polysaccharides 2.2.1 Infrared spectrum analysis From the infrared spectra of CSA and MPS ( Figure 4 ) It can be seen that MPS retains the basic skeleton structure of CSA, at 3500cm -1 The absorption peaks around 1238 cm-1 are attributed to the characteristic stretching vibration absorption peaks of the polyhydroxyl and amino groups in the compound. Compared with LMCS, the absorption peak of MPS in this range is significantly narrower, indicating that the hydroxyl and amino groups in the sulfonated polysaccharide are reduced. In addition, the absorption peak at 1238 cm-1 in MPS -1 The S=O asymmetric peak at 1262 cm -1 Compared with the S=O asymmetric peak at 858 cm, the absorption peak intensity of S=O in both cases is significantly increased, suggesting that MPS contains more sulfonic acid groups, but the absorption peak at 858 cm -1 The intensity of the sulfate group at the C-4 position of galactosamine remains unchanged. A new high-intensity absorption peak appears in MPS at 815 cm -1According to the literature, this should be attributed to the sulfate stretching vibration peak at the C-6 position of galactosamine. The above results indicate that MPS is highly sulfonated. Studies have shown that the C-2 position on the glucuronic acid in chondroitin sulfate is also prone to sulfonate substitution, and sulfonation at the C-3 position is relatively rare. Polysulfated chondroitin sulfate (PSCS) tries to sulfonate the C-4 and C-6 positions of galactosamine in the disaccharide basic unit and the C-2 and C-3 positions of glucuronic acid as much as possible. However, from the above infrared spectrum analysis results, it can only be concluded that the C-6 position of galactosamine in chondroitin sulfate A is successfully sulfonated, which is chondroitin sulfate E (CSE), and whether the C-2 and C-3 positions of glucuronic acid are sulfonated at the same time needs to be further confirmed by nuclear magnetic resonance.

[0019] 2.2.2 NMR spectrum analysis Weigh 30 mg of CSA and MPS respectively and dissolve them in 0.5 mL D2O for freeze-drying substitution. The freeze-dried samples are redissolved in 0.5 mL D2O and placed in NMR tubes and calibrated with acetone for NMR analysis. The results are as follows: (where U represents glucuronic acid in chondroitin sulfate A, N represents galactosamine in chondroitin sulfate A, 4s represents sulfonation at C-4 of galactosamine, 6s represents sulfonation at C-6 of galactosamine, 2s represents sulfonation at C-2 of glucuronic acid, and 3s represents sulfonation at C-3 of glucuronic acid).

[0020] Through one dimension 1 H spectrum ( Figure 5 )、 13 C spectrum ( Figure 6 ) and two-dimensional HSQC spectra ( Figure 7 ) Nuclear magnetic resonance analysis of CSA and MPS shows that: 1) in CSA 13 In the anomeric carbon region of the C spectrum, 103.7ppm and 104.3ppm are respectively attributed to the C-1 position of glucuronic acid after sulfonation of the C-4 and C-6 positions of galactosamine, and 100.9ppm is attributed to the C-1 position of galactosamine; in the high-field region of the non-anomeric carbon, the strong signal peak at 61.0ppm is attributed to the C-6 signal of galactosamine after sulfonation of the C-4 position, and there is a weak signal peak at 67.5ppm, which belongs to the C6 signal after sulfonation of the C-4 and C-6 positions of galactosamine; in the CSA 1In the H spectrum, 4.34ppm and 4.31ppm are respectively attributed to the H-1 position of glucuronic acid after sulfonation of galactosamine C-4 and C-6, and 4.41ppm is attributed to the H-1 position of galactosamine; the stronger signal peak at 3.64ppm is attributed to the H-6 signal of galactosamine after sulfonation of C-4, while the weaker signal peak at 4.07ppm is attributed to the H-6 signal after sulfonation of C-4 and C-6 of galactosamine. Since the C-6 position of galactosamine in CSA is only partially sulfonated, 13 The signal peak at 67.5ppm in the C spectrum and 1 The H spectrum is weaker, and combined with the two different C1 / H1 positions of glucuronic acid in the anomeric carbon-hydrogen region, it can be seen that the galactosamine in LMCS is mainly sulfonated at the C-4 position, and part of the C-6 position is sulfonated. 2) One-dimensional comparison with CSA 13 Compared with the one-dimensional C spectrum of MPS 13 The anomeric carbon region of the C spectrum is relatively concentrated, and the C-1 positions of glucuronic acid and galactosamine are difficult to distinguish. This is because the C-2 position of glucuronic acid is sulfonated, causing its C-1 position to shift to a higher field. In the non-anomeric carbon region, it can be clearly seen that the C-6 signal peak (61.0ppm) of galactosamine, which originally belonged to the sulfonated C-4 position, has disappeared, leaving only the C-6 of galactosamine after 4s and 6s are double-sulfated, indicating that the C-6 position of galactosamine in S3-LMCS has basically been sulfonated. At the same time, at 77.1 A new signal peak appeared at ppm. This peak was caused by the C-2 position of glucuronic acid being sulfonated and moving about 5 ppm to a low field. The C-2 position of glucuronic acid that was not sulfonated was still retained at 72.0 ppm in MPS, indicating that the C-2 position of glucuronic acid was partially sulfonated. We can also observe that the C4 position signal peak of glucuronic acid originally located at 80.2 ppm disappeared, and a new signal peak appeared at 75.2 ppm. The difference between the two was about 5 ppm, suggesting that the signal peak should belong to the C-4 position in MPS. It was just that the C-3 position of glucuronic acid was sulfonated, causing its C-4 position signal peak to move to a high field. The C-3 position of glucuronic acid still had a signal peak at 76.3 ppm, only part of which shifted to a low field, suggesting that the C-3 position of glucuronic acid was also partially sulfonated. 3) By comparing the HSQC spectra of CSA and MPS, we can also see that new carbon-hydrogen related signal peaks appeared in MPS after the sulfonation of glucuronic acid C-2 and C-3, located at 77.4 / 3.89 and 80.0 / 4.41 respectively, while the signal peak originally located at 61.2 / 3.63 disappeared, leaving the signal peak at 67.4 / 4.14 after the double sulfation of galactosamine C-4 and C-6.

[0021] In summary, we can infer that almost all of the C6 position of galactosamine in LMCS has been sulfonated, mainly because its steric hindrance is small and the sulfate group is easy to attack; while the steric hindrance of C2 and C3 of glucuronic acid in LMCS is large, and C3 is the most difficult to sulfonate. Therefore, we can see from NMR that most of the C2 position of glucuronic acid in S3-LMCS has been sulfonated, while the proportion of sulfonation at C3 is less, but it is still partially sulfonated. Therefore, the possible chemical structure of MPS is as follows: n = 12

[0022] 1. Study on the whitening activity of MPS Using B16 mouse melanoma cells as experimental subjects, the biological activity of MPS in whitening was detected by MTT and tyrosinase activity test experiments.

[0023] 1.1 Take B16 cells in the logarithmic growth phase and add 1×10 4 The number of cells was inoculated into a 96-well plate and allowed to adhere overnight. Complete medium containing different concentrations of MPS was given to each well, and a control group was set up. The culture was continued for 24 hours, and three replicates were set up for each group. The cell morphology under different conditions was observed the next day. The results are as follows Figure 8 The morphology of B16 cells treated with MPS was shown to differentiate into normal epithelial cells. 10 μL of MTT was added to each well, incubated at 37°C for 2-3 h, and the supernatant was discarded. 150 μL of DMSO was added to each well, shaken to dissolve, and the absorbance was measured at a wavelength of 490 nm to calculate the cell survival rate. The results are shown in Fig. 9 The experimental results showed that MPS had no inhibitory effect on the proliferation of B16 cells. On the contrary, it promoted the proliferation of B16 cells to a certain extent at 125 and 250 μg / mL.

[0024] 1.2 Take B16 cells in the logarithmic growth phase and add 5×10 5 The number of cells was inoculated in a 6-well plate and adhered overnight. Complete medium containing different concentrations of MPS was given respectively, and a control group was set up at the same time. The culture was continued for 24 hours, and three replicates were set up for each group. The supernatant was discarded, and the cells were washed twice with PBS. 200 μL of cell lysis buffer was added to each well to lyse the cells. The cells were centrifuged at 1,2000 rpm for 5 minutes, 80 μL of the supernatant was taken to a 96-well plate, 10 μL of 1% L-DOPA was added to each well, and the absorbance of each well was measured at 490 nm after incubation at 50°C for 45 minutes. The tyrosinase activity was calculated. The results are shown in Fig.10 The experimental results showed that MPS could effectively inhibit the tyrosinase activity in B16 cells compared with the blank control group.

[0025] 2. Study on the anti-aging activity of MPS In this example, a cell senescence model was constructed by stimulating HaCaT cells with H2O2. The effect of MPS on the proliferation of HaCaT cells under H2O2 stimulation was detected by MTT cell proliferation assay to explore the anti-cell senescence function of MPS. HaCaT cells in logarithmic growth phase were taken at 1×10 4 The number of cells was inoculated in a 96-well plate and adhered to the wall overnight. A blank control group, groups treated with H2O2 at different concentrations, and groups treated with MPS at different concentrations were set up. After 24 h of treatment, 10 μL of MTT was added to each well. After incubation at 37°C for 2-3 h, the supernatant was discarded, 150 μL of DMSO was added to each well, and the cells were dissolved by shaking. The absorbance was measured at a wavelength of 490 nm, and the cell survival rate was calculated. The results are shown in the figure. Figure 11-12 shown. Fig.11 The experimental results shown in the figure show that 0.8, 0.9 and 1 mM H2O2 can effectively inhibit the proliferation of HaCaT cells, and MPS (0.3-1 mg / mL) has no significant effect on the proliferation of HaCaT cells, indicating that MPS has a certain safety within this range. HaCaT cells in the logarithmic growth phase were taken at 1×10 4 The number of cells was inoculated in a 96-well plate, and 0.8 mM H2O2 was selected to construct the HaCaT cell aging model. At the same time, the cells were treated with different concentrations of MPS. After culturing at 37°C for 24 h, 10 μL of MTT was added to each well. After incubation at 37°C for 2-3 h, the supernatant was discarded, 150 μL of DMSO was added to each well, and the cells were dissolved by shaking. The absorbance was measured at a wavelength of 490 nm, and the cell survival rate was calculated. The results are shown in the figure. Fig.13 As shown. The results showed that compared with the blank control group, 0.8mM H2O2 could effectively inhibit the proliferation of HaCaT cells, and the cell survival rate was reduced to 74.7%. When treated with different concentrations of MPS, the cell survival rate recovered to 100% or above, indicating that MPS can reverse the inhibition of HaCaT cell proliferation caused by H2O2. The above experimental results preliminarily show that MPS has a certain inhibitory effect on the senescence of HaCaT cells.

[0026] 3. Study on the anti-inflammatory activity of MPS In this example, LPS (1 μg / mL) was used to induce RAW264.7 to construct an inflammatory cell model. The MTT cell proliferation assay was used to detect the effect of MPS on the proliferation of RAW264.7 cells under LPS stimulation. At the same time, the NO detection kit was used to detect the content of NO in the culture supernatant to explore the anti-inflammatory activity of MPS. RAW264.7 cells in the logarithmic growth phase were taken at 2×10 4The number of cells was inoculated in a 96-well plate and adhered to the wall overnight. A blank control group, a LPS (1 μg / mL) treatment group, and a MPS (250, 500, 1000 μg / mL) and LPS (1 μg / mL) co-treatment group were set up. After 24 h of treatment in a 37°C constant temperature incubator, the supernatant was collected, 100 μL of fresh culture medium and 10 μL of MTT were added to each well, and the supernatant was discarded after further incubation at 37°C for 2-3 h. 150 μL of DMSO was added to each well, and the solution was dissolved by shaking. The absorbance was measured at a wavelength of 490 nm, and the cell survival rate was calculated. The results are shown in Fig.14 As shown. The experimental results showed that the LPS treatment group alone and the LPS and MPS co-treatment group had no significant inhibitory effect on the proliferation of RAW264.7 cells. Compared with the blank control group, MPS (1 mg / mL) showed a certain pro-proliferation effect on LPS-stimulated RAW264.7 cells, and the cell survival rate increased by 19%. However, the results of the NO detection experiment ( Fig.15 ) showed that compared with the blank control group, the LPS treatment group effectively promoted the NO release of RAW264.7 cells; when LPS and MPS (250 and 500 μg / mL) were co-treated, the NO release of RAW264.7 cells was significantly reduced compared with the LPS treatment group. The above experimental results suggest that MPS can effectively inhibit LPS-induced NO release in RAW264.7 cells within a certain concentration range, and MPS has potential anti-inflammatory effects.

Claims

1. A polysulfonate mucopolysaccharide MPS, characterized in that It is a polysulfonated degradable polysaccharide with a molecular weight of 5,000-15,000 Da, which is composed of disaccharide units alternately formed by 1,4-linked glucuronic acid and 1,3-linked N-acetylgalactosamine. It has the following structure: n = 11-13.

2. The polysulfonated mucopolysaccharide MPS according to claim 1, characterized in that The molecular weight is 7,766 Da.

3. The method for preparing the polysulfonated mucopolysaccharide MPS according to claim 1, characterized in that It includes the following steps: (1) Degradation of chondroitin sulfate A (CSA): CSA is degraded by hydrogen peroxide, the reaction is terminated, and the dialyzed solution is obtained by deionized water dialyzing. The dialyzed solution is concentrated, and the concentrated solution is freeze-dried to obtain degraded polysaccharide; (2) Sulfonation of degraded polysaccharides: Sulfonation of degraded polysaccharides was carried out by adding chlorosulfonic acid formamide, dialyzing with deionized water, and freeze-drying to obtain polysulfonated mucopolysaccharide MPS.

4. Use of the polysulfonated MPS according to claim 1 in the preparation of a tyrosinase inhibitor drug.

5. Use of the polysulfonic acid sticky MPS according to claim 1 in the preparation of an additive as an anti-aging inhibitor.

6. Use of the polysulfonated MPS according to claim 1 in the preparation of inflammation inhibitor drugs.

Citation Information

Cited By

  • Preparation method of polysulfonic acid mucopolysaccharide

    CN122541606A

  • Use of polysulfated glycosaminoglycans in the preparation of products for wrinkle repair

    CN122849287A